News

• July 28, 2022

  Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain Disorders >

  BALA CYNWYD, Pa. , July 28, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that preclinical studies evaluating CTI-1601’s effects on gene expression

• June 28, 2022

  Larimar Therapeutics Announces Oral Presentation at the Upcoming Gordon Research Conference on Mitochondria and Chloroplasts >

  BALA CYNWYD, Pa. , June 28, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that biomarker studies that have identified genes that are differentially

• June 2, 2022

  Larimar Therapeutics Announces Upcoming Scientific Conference Presentations >

  BALA CYNWYD, Pa. , June 02, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced upcoming presentations at the United Mitochondrial Disease Foundation

• May 19, 2022

  Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress >

  BALA CYNWYD, Pa. , May 19, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that data from the Company’s Phase 1 clinical program evaluating CTI-1601 as

• May 12, 2022

  Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results >

  - CTI-1601 Type C Meeting to discuss clinical hold has been granted by the U.S. Food and Drug Administration and is scheduled for early in the third quarter of 2022 - Cash at March 31, 2022 of $62.6 million provides projected cash runway into the third quarter of 2023 BALA CYNWYD, Pa.

• March 25, 2022

  Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results >

  BALA CYNWYD, Pa. , March 25, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its full year 2021 operating and financial results.

• February 14, 2022

  Larimar Therapeutics Provides Update on CTI-1601 Clinical Program >

  BALA CYNWYD, Pa. , Feb. 14, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has received feedback from the U.S.

• November 22, 2021

  Larimar Therapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference >

  BALA CYNWYD, Pa. , Nov. 22, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in virtual 1x1 investor meetings at

• November 15, 2021

  Larimar Therapeutics to Participate in the Guggenheim Virtual Neuro/Immunology Conference >

  BALA CYNWYD, Pa. , Nov. 15, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in 1x1 investor meetings at the

• November 12, 2021

  Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results >

  BALA CYNWYD, Pa. , Nov. 12, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its third quarter and year to date September 30, 2021 operating and financial

• September 16, 2021

  Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event >

  BALA CYNWYD, Pa. , Sept. 16, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in 1x1 investor meetings at the

• September 2, 2021

  Larimar Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference >

  BALA CYNWYD, Pa. , Sept. 02, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon , MD, President and Chief Executive Officer of

• August 19, 2021

  Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress >

  BALA CYNWYD, Pa. , Aug. 19, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that David Bettoun, PhD, Vice President Discovery & Non-Clinical R&D of

• August 12, 2021

  Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results >

  - Reported positive proof-of-concept and dose response data from Phase 1 program evaluating CTI-1601 in patients with Friedreich’s ataxia (FA) - Subcutaneous injections of CTI-1601 at doses of 50 mg or 100 mg resulted in frataxin levels in buccal cells of FA patients that were at or in excess of

• July 8, 2021

  Larimar Therapeutics to Present at the William Blair Biotech Focus Conference 2021 >

  BALA CYNWYD, Pa. , July 08, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon , MD, President and Chief Executive Officer of

• June 11, 2021

  Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference >

  BALA CYNWYD, Pa. , June 11, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon , MD, President and Chief Executive Officer of

• May 25, 2021

  Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing >

  BALA CYNWYD, Pa. , May 25, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich’s ataxia (FA) and other complex rare diseases, today announced that the United States Food and Drug

• May 21, 2021

  Larimar Therapeutics Announces $95 Million Private Placement Financing >

  BALA CYNWYD, Pa. , May 21, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich’s ataxia (FA) and other complex rare diseases, today announced that it has executed a securities purchase

• May 20, 2021

  Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia >

  BALA CYNWYD, Pa. , May 20, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich’s ataxia (FA) and other complex rare diseases, today announced that the European Medicines Agency (EMA)

• May 11, 2021

  Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia >

  Data demonstrate proof-of-concept by showing that daily subcutaneous injections of CTI-1601 for up to 13 days resulted in dose-dependent increases in frataxin levels from baseline compared to placebo in all evaluated tissues Data show that frataxin levels achieved in peripheral tissues (buccal

• May 10, 2021

  Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results >

  - Topline data from placebo-controlled Phase 1 program in Friedreich's ataxia patients to be announced tomorrow, May 11, 2021 - Management to discuss during webcast and conference call at 8 a.m. ET - Cash and investments of $81.4 million as of March 31, 2021 BALA CYNWYD, Pa.

• March 4, 2021

  Larimar Therapeutics Reports Fourth Quarter and Full Year 2020 Operating and Financial Results >

  Reported preliminary Phase 1 findings from a Single Ascending Dose (SAD) trial that suggest single subcutaneous injections of CTI-1601 were well tolerated at doses up to 100 mg in Friedreich's   ataxia (FA) patients Placebo-controlled Phase 1 trials in FA patients remain on track for topline data

• February 18, 2021

  Larimar Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference >

  BALA CYNWYD, Pa. , Feb. 18, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon , MD, President and Chief Executive Officer of

---

View all News >